AI made execution free. Knowing first is the whole game now.
The advantage goes to whoever is first into the right conversations, most often. Fundz stacks those odds: more of the moments that create demand than anyone else catches, as they happen, matched to who you sell to, with the decision maker to call. Now it answers in Claude too: ask for today’s leads and who to reach, then write the note in the same window. Not a feed. Not a list you rent. A system for being first.
Trusted by
Acquiring Company
Eli Lilly
Acquired Company
AtaiBeckley
IndianapolisUnited StatesManufacturingBiotechnologyHealth CareMedicalPharmaceuticalBiotechnologyHealth CareTherapeuticsDescription
Eli Lilly finalized its acquisition of AtaiBeckley on September 11, paying $6.75 per share plus potential milestones. This transaction turns AtaiBeckley into a wholly owned subsidiary, ceasing its operations as an independent entity. The deal is valued at approximately $2.8 billion, with contingent rights that could raise it to $3.8 billion. Eli Lilly is interested in AtaiBeckley's innovative psychiatric research.
Fundz sees it the moment Eli Lilly makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
M&A Insights
Based on deal dataFrequently asked
Who acquired AtaiBeckley?
AtaiBeckley was acquired by Eli Lilly, based in Indianapolis. The deal was reported on September 20, 2026. Eli Lilly is a global healthcare and pharmaceutical company focused on the discovery, development, and delivery of innovative pharmaceutical medicines, vaccines, and consumer healthcare products. Eli Lilly is publicly traded (LLY) and operates in Manufacturing.
When did Eli Lilly acquire AtaiBeckley?
Eli Lilly's acquisition of AtaiBeckley was reported on September 20, 2026. Eli Lilly finalized its acquisition of AtaiBeckley on September 11, paying $6.75 per share plus potential milestones. This transaction turns AtaiBeckley into a wholly owned subsidiary, ceasing its operations as an independent entity. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does AtaiBeckley do?
AtaiBeckley Inc. is a biotechnology company based in Delaware, primarily focused on the development of novel therapeutics for mental health disorders. It is privately held, operating in Biotechnology, and is based in United States.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.
5 screens from a live account. No signup.